Heat Biologics reports wider net loss in 2013

Posted by David Bracken on April 1, 2014 

Heat Biologics reported a wider net loss in 2013 that it attributed to an increase in research and development, and clinical and regulatory expenses.

The small Chapel Hill drug-development company has no drugs on the market but is developing treatments for lung cancer and bladder cancer.

Heat Biologics had a net loss of $6.6 million, or $2.42 per share, last year, compared with a loss of $2.47 million, or $1.32 per share, in 2012.

Research and development expenses increased from $903,000 in 2012 to $2.74 million last year. Most of that increase was related to pre-manufacturing costs for two of Heat’s vaccines that will be used in clinical trials. Heat Biologics’ clinical and regulatory expenses increased $1.144 million, and was largely related to the launch of clinical trials for the two vaccines.

The company raised $25 million in an initial public offering of stock in July. Heat Biologics’ shares, which began trading at $10 per share in July, closed Tuesday at $6.57, down 12 cents.

As of the end of last year, Heat Biologics had $21.9 million in cash and cash equivalents. The company estimates that it has enough cash to fund its operations through the second half of 2015.

News & Observer is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere in the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

Commenting FAQs | Terms of Service